Neurological Diseases Protein Biomarker Detection Service

Neurological diseases are a group of medical conditions that affect the nervous system and can be divided into neurodegenerative and neurodevelopmental diseases. Early diagnosis of neurological disorders can be made by detecting protein biomarkers, which is benefit the early treatment of patients.

Early detection of protein biomarkers is essential for neurological diseases diagnosis. As a professional analyte detection company, CD BioSciences is committed to providing efficient neurological diseases protein biomarker detection service.

Neurological Diseases Protein Biomarker Detection by CRIPSR-Cas System

CRISPR-Cas is originated from the adaptive immune system of bacteria and archaea. In the recent years, the continuous development of CRISPR-Cas system has made it an effective tool for analyte detection. In the field of bioanalysis, the CRISPR-Cas system has the advantage of precise targeting and efficient cleavage of targeted or non-targeted nucleic acids, and thus can be used for protein biomarker detection in neurological diseases.

CRISPR-Cas9	CRISPR-Cas13
A new peptide display platform, PICASSO, has been developed using CRISPR-Cas9 technology. Using this platform, DNA molecules can be placed at specific locations on a surface, and each protein in the mixture then self-assembles to the corresponding DNA sequence, and the resulting DNA template protein microarrays allow you to quickly identify antibodies in clinical samples, or to identify any protein of interest to you.	Based on the signal amplification capability of the CRISPR-Cas system, researchers have developed an enzyme-linked immunosorbent assay using CRISPR-Cas13a as a signal amplification strategy, referred to as CLISA. The method allows for the detection of multiple neurological diseases protein biomarkers for disease diagnosis. The CARPID detection uses the CRISPR-Cas13d system to specifically tract a BASU biotin transferase fused to it to the vicinity of lncRNA in living cells, biotinylating the neighboring protein, which is subsequently separated using streptavidin-coupled magnetic beads, followed by label-free quantitative comparative analysis of the separated protein by mass spectrometry to confirm the binding of lncRNA proteins.

CRISPR-Cas9

CRISPR-Cas13

A new peptide display platform, PICASSO, has been developed using CRISPR-Cas9 technology. Using this platform, DNA molecules can be placed at specific locations on a surface, and each protein in the mixture then self-assembles to the corresponding DNA sequence, and the resulting DNA template protein microarrays allow you to quickly identify antibodies in clinical samples, or to identify any protein of interest to you.

Based on the signal amplification capability of the CRISPR-Cas system, researchers have developed an enzyme-linked immunosorbent assay using CRISPR-Cas13a as a signal amplification strategy, referred to as CLISA. The method allows for the detection of multiple neurological diseases protein biomarkers for disease diagnosis.

The CARPID detection uses the CRISPR-Cas13d system to specifically tract a BASU biotin transferase fused to it to the vicinity of lncRNA in living cells, biotinylating the neighboring protein, which is subsequently separated using streptavidin-coupled magnetic beads, followed by label-free quantitative comparative analysis of the separated protein by mass spectrometry to confirm the binding of lncRNA proteins.

Our Services

Utilizing the CRISPR-Cas system's ability to specifically identify and cleave nucleic acid sequences, CD BioSciences offer highly sensitive neurodegenerative diseases protein biomarker detection service. In addition, we also provide detection services for nucleic acids, metal ions and small molecules.

Our DeteCas™ platform can detect protein biomarkers for different neurodegenerative diseases, including but not limited to the followings.

Neurodegenerative Diseases

MAPK14(mitogen-activated protein kinase14)
lgD (immunoglobulin D)
TRAMP (tyrosine-rich acidic matrix protein)
EPHB2(ephrin type-B receptor 2)
suPAR (soluble urokinase plasminogen activator receptor)

Neurodevelopmental Diseases

IL-6(interleukin 6)
α-synuclein
NFP (neurofilament protein)
Aβ (amyloid β-protein)
TGF-β1 (transforming growth factor-β1)

Process of Our Service

Advantages of Our Service

High sensitivity for detection of low concentration substances.
High detection efficiency using an optimized CRISPR-Cas system.
Different detection solutions to meet different research needs.
Regular reporting of experimental progress.

CD BioSciences provides affordable, qualified and hassle-free neurological diseases protein biomarker detection service to our global clients. We guarantee on-time delivery of results. We are available to you 24 hours a day, so please feel free to contact us.

References

Chen, Q., et al. CRISPR/Cas13a Signal Amplification Linked Immunosorbent Assay for Femtomolar Protein Detection. Analytical Chemistry. 2020, 1(92): 573-577.
Xie, S.Y., et al. Advancing sensing technology with CRISPR: From the detection of nucleic acids to a broad range of analytes-A review. Analytica Chimica Acta. 2021, 338848.

For research use only. Not intended for any clinical use.